Oncotarget

Research Papers:

MiR-205 as a promising biomarker in the diagnosis and prognosis of lung cancer

Jing-Hua Li, Shan-Shan Sun, Ning Li, Peng Lv, Shu-Yang Xie _ and Ping-Yu Wang

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:91938-91949. https://doi.org/10.18632/oncotarget.20262

Metrics: PDF 1458 views  |   HTML 2079 views  |   ?  


Abstract

Jing-Hua Li1,2, Shan-Shan Sun1, Ning Li1, Peng Lv1, Shu-Yang Xie2 and Ping-Yu Wang1,2

1Department of Epidemiology, Binzhou Medical University, YanTai, ShanDong 264003, P.R. China

2Key Laboratory of Tumor Molecular Biology in Binzhou Medical University, Department of Biochemistry and Molecular Biology, Binzhou Medical University, YanTai, ShanDong 264003, P.R. China

Correspondence to:

Shu-Yang Xie, email: [email protected]

Ping-Yu Wang, email: [email protected]

Keywords: biomarker, miR-205, lung cancer, diagnosis, prognosis

Received: May 26, 2017     Accepted: July 13, 2017     Published: August 14, 2017

ABSTRACT

MicroRNA-205 (miR-205) was revealed as a novel diagnostic and prognostic biomarker for lung cancer, but the results in the published papers were inconsistent. This meta-analysis aimed to investigate the diagnostic and prognostic roles of miR-205 in patients with lung cancer. Totally, 16 eligible articles were included, among which 10 articles investigated the diagnostic value of miR-205, 5 articles examined its prognostic values, and 1 article studied both diagnostic and prognostic values. For the diagnostic meta-analysis, the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and the overall area under the curve of miR-205 for patients with lung cancer were 0.88 (95% CI = 0.78 – 0.94), 0.78 (95% CI = 0.66 – 0.86), 4.00 (95% CI = 2.47 – 6.49), 0.16 (95% CI = 0.08 – 0.30), 25.86 (95% CI = 9.29 – 71.95), and 0.90 (95% CI = 0.87 – 0.92), respectively, indicating that miR-205 is a useful biomarker for diagnostic of lung cancer. The subgroup analysis further demonstrated that miR-205 had an excellent overall accuracy for detection with tissue samples compare with blood samples. For the prognostic meta-analysis, the pooled outcome of the disease-free survival and recurrence-free survival analyses revealed that increased miR-205 levels had a protective role in the prognosis of patients with lung cancer (pooled HR = 0.86, 95% CI: 0.78-0.96, z = 2.83, P = 0.005). In conclusion, miR-205 may be a promising biomarker for detection, predicting the recurrence of patients with lung cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20262